Akili Sees 2023 Non-GAAP Total Operating Expenses $55M-$60M; Sees Non-Prescription Business Model to Operate At 60-70% Gross Margins By Late 2025
Portfolio Pulse from Bill Haddad
Akili Interactive Labs expects its non-GAAP total operating expenses to be between $55M-$60M in 2023. The company also anticipates its non-prescription business model to operate at 60-70% gross margins by late 2025.
September 13, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Akili Interactive Labs expects its 2023 non-GAAP total operating expenses to be $55M-$60M and its non-prescription business to operate at 60-70% gross margins by late 2025.
The news directly pertains to Akili Interactive Labs' financial projections. While the expected increase in operating expenses could be a concern, the anticipated high gross margins for its non-prescription business could offset this. The net impact on the stock price is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100